Charles River Operating Income Over Time
| CRL Stock | USD 183.70 17.92 8.89% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Charles River Performance and Charles River Correlation. Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Charles River. Projected growth potential of Charles fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Charles River assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.17) | Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets |
Understanding Charles River Labora requires distinguishing between market price and book value, where the latter reflects Charles's accounting equity. The concept of intrinsic value - what Charles River's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Charles River's price substantially above or below its fundamental value.
It's important to distinguish between Charles River's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Charles River should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Charles River's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Charles River Labora and related stocks such as Qiagen NV, Bio Rad Laboratories, and Baxter International Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QGEN | 4.7 M | 99.6 M | 169.8 M | 63.3 M | 161.7 M | 179.5 M | 98.8 M | 153.4 M | 266.6 M | (26.1 M) | 386.4 M | 630.1 M | 531.5 M | 409.9 M | 97.7 M | 520.3 M | 546.3 M |
| BIO | 8.7 M | 295.2 M | 264.1 M | 169.5 M | 150 M | 166.7 M | 53.2 M | 116.7 M | (108.6 M) | 229.7 M | 421.3 M | 500.3 M | 482.6 M | 337.8 M | 269 M | 309.4 M | 324.8 M |
| BAX | 265 M | 2.9 B | 2.8 B | 496 M | 656 M | 449 M | 745 M | 1.3 B | 1.6 B | 1.8 B | 1.6 B | 1.4 B | (2.8 B) | 707 M | 14 M | 16.1 M | 15.3 M |
| AVTR | 60.3 M | 60.3 M | 60.3 M | 60.3 M | 60.3 M | 60.3 M | 9.9 M | (210.4 M) | 413.5 M | 551.8 M | 706.8 M | 972.2 M | 1.1 B | 696.4 M | 1.1 B | 1.2 B | 1.3 B |
| RVTY | 63.9 M | 117.9 M | 200.8 M | 258.8 M | 230.5 M | 266.8 M | 305.7 M | 304.6 M | 371 M | 405.5 M | 1 B | 1.3 B | 781.1 M | 399.5 M | 410.5 M | 356.6 M | 268.7 M |
| PEN | 3.4 M | 3.4 M | 3.4 M | (1.1 M) | 3 M | 4.2 M | (1.4 M) | 1.2 M | (852 K) | 47.5 M | (38.9 M) | (7.5 M) | 6.1 M | 73.6 M | 9.3 M | 10.7 M | 8.3 M |
| DVA | 17.2 M | 1.2 B | 1.3 B | 1.6 B | 1.8 B | 1.1 B | 2 B | 1.8 B | 1.5 B | 1.6 B | 1.7 B | 1.8 B | 1.3 B | 1.6 B | 2.1 B | 2 B | 1.1 B |
| RNA | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (10.5 M) | (17.3 M) | (44.3 M) | (118.1 M) | (178.9 M) | (235.6 M) | (378.9 M) | (341 M) | (324 M) |
| CAI | 3.7 M | 64.3 M | 90.6 M | 101.4 M | 97 M | 68.1 M | 66 M | 105.7 M | 148.8 M | 130.3 M | 139.1 M | (315.8 M) | (315.8 M) | (319.6 M) | (257.1 M) | (231.4 M) | (219.8 M) |
Charles River Labora and related stocks such as Qiagen NV, Bio Rad Laboratories, and Baxter International Operating Income description
Operating Income is the amount of profit realized from Charles River Labora operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Charles River Laboratories is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Charles River Laboratories | CRL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 251 Ballardvale Street, |
| Exchange | New York Stock Exchange |
USD 183.7
Check out Charles River Performance and Charles River Correlation. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Charles River technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.